NKE · DEEP VALUE BRIEFING

NIKE, Inc. (NKE)

published Sep 25, 2026 · price now $33.84 · market cap $50.1B

WATCH · low confidence — the research’s call on buying at the price it saw, not advice to you.

Information only, not investment advice. Written by AI research agents from SEC filings and market data, and it can be wrong. Check the model below before relying on any of it.

Executive Briefing

Verdict: Nike remains a WATCH at $35.99.

  • Nike appears impaired, not broken: its global brand, distribution network, 42.9% gross margin, and reported 22.6% ROIC indicate substantial recovery capacity.
  • The apparent 17.1× P/E is attractive only if approximately $2.10 of EPS converts into sustainable owner earnings. That has not been established.
  • A valuation near $40 would provide only about 10% upside, insufficient for an unproven turnaround. Nike currently warrants a roughly 20%–30% margin of safety, not the smaller discount appropriate for a predictable compounder.
  • The 46% decline and bearish chart do not prove permanent impairment, but they likely reflect continuing estimate risk. Options data are unusable because reported open interest is zero.
  • Retain the original defensive watchlist plan. A moderate-risk investor may take only a 0.5%–1% starter position, with additional purchases tied to operating improvement—not merely a lower share price.

Key Arguments from the Debate

Risky Analyst: Begin measured accumulation

The bullish case rests on several credible points:

  • Nike retains unusually valuable assets: global recognition, athlete relationships, sourcing scale, wholesale reach, direct customer relationships, and a deep product archive.
  • A 42.9% gross margin and 22.6% reported ROIC are inconsistent with a fundamentally broken franchise.
  • At 17.1× implied earnings following a 46% decline, the shares are no longer priced as an uninterrupted premium-growth company.
  • Nike need not recover all lost market share. Revenue stabilization, better full-price selling, modest margin recovery, and productive wholesale repair could generate acceptable returns.
  • Waiting for complete confirmation could result in buying substantially higher because turnaround stocks often rerate before reported results fully recover.

What is persuasive: The franchise has multiple recovery paths, and excessive reliance on trailing price trends could cause investors to miss an inflection.

What is unproven: The analyst assumes current earnings are trough-adjacent and that the market already discounts most operating risk. Neither assumption is supported by cash-flow evidence.

Safe Analyst: Preserve capital and demand proof

The conservative case properly identifies the central uncertainty:

  • The 17.1× P/E is meaningful only if implied EPS of roughly $2.10 is sustainable.
  • If normalized earnings are closer to $1.50, Nike trades at approximately 24× earnings—a demanding valuation for a company still losing momentum.
  • Gross margin can remain respectable while operating expenses, promotions, and weak volume damage operating profit and free cash flow.
  • Reported ROIC is backward-looking and may be elevated because internally generated brand investment is expensed rather than recorded as invested capital.
  • Comparable upside to the upper $40s and downside into the $20s do not establish favorable asymmetry without a higher probability of stabilization.
  • Position sizing limits portfolio damage but does not improve intrinsic value or expected return.

What is persuasive: The bull case has not reconciled accounting earnings to normalized free cash flow. Buying simply because the shares have declined would be price anchoring.

Where it may be too strict: Requiring every region, margin, inventory, and cash-flow measure to improve for two full quarters could surrender too much upside. Selective early evidence can be sufficient.

Neutral Analyst: Small exposure with operating gates

The neutral proposal offers the best tactical compromise:

  • Permit a 0.5%–1% starter position for a moderate-risk investor.
  • Cap eventual exposure around 2%–3%.
  • Do not add solely because the stock falls.
  • Require at least two substantive improvements before a second tranche, such as lower promotional intensity, better inventory discipline, product traction, margin recovery, or improved cash conversion.
  • Avoid short-dated options because liquidity is unverified and turnaround timing is uncertain.

This approach recognizes Nike’s recovery option while preventing admiration for the franchise from becoming an oversized commitment.

Risk Judge’s Assessment

1. Business risk is meaningful but not yet permanent impairment

Nike still possesses a defensible global platform. Competitors such as On, Hoka, and Adidas do not need to destroy Nike to pressure shareholder returns, however. They only need to capture enough high-value demand to:

  • increase Nike’s marketing and product-development requirements;
  • reduce full-price sell-through;
  • sustain promotional activity;
  • weaken incremental margins; and
  • prolong the repair of wholesale relationships.

Nike is simultaneously addressing product innovation, North America, China, inventory, wholesale distribution, and direct-to-consumer execution. That is a broad turnaround, not a single-quarter fluctuation.

The evidence nevertheless does not support labeling Nike a structurally declining or distressed business. No data show interest coverage below 1×, an Altman-Z distress condition, or an immediate solvency problem. Balance-sheet and lease information are missing, so financial strength should be verified rather than assumed.

2. Current profitability demonstrates capacity, not recovery

The reported metrics are encouraging:

  • Gross margin: 42.9%
  • ROIC: 22.6%
  • ROE: 20.9%
  • ROA: 8.1%

They indicate that meaningful economic value remains in the franchise. But they are insufficient to establish that incremental investment is currently earning attractive returns.

ROE is less informative after years of repurchases that reduced book equity. ROIC may understate the economic capital invested in decades of brand building. The key questions are therefore:

  • Is ROIC stabilizing or declining?
  • Are current innovation and marketing expenditures generating profitable sales?
  • Is gross-margin resilience translating into operating-margin recovery?
  • Does net income convert into recurring free cash flow?

Until those questions are answered, historical quality should not receive the same valuation concession as current predictability.

3. The valuation is plausible, but the margin of safety is thin

At $35.99 and 17.14× earnings, implied EPS is approximately $2.10. Two interpretations produce very different conclusions:

  • If $2.10 approximates sustainable owner earnings: Nike may be modestly undervalued, and low- to mid-single-digit growth could support a value in the low-to-mid $40s.
  • If normalized owner earnings are closer to $1.50: the stock trades near 24× earnings and remains expensive for an unresolved turnaround.

The reverse-DCF claim that the market requires only around 3% cash-flow growth is useful only if its starting cash flow is normalized. If current earnings exceed sustainable cash generation, Nike must first recover lost economics before achieving genuine growth.

A value around $40 provides only approximately 11% upside from the current price. A 10%–15% discount can be enough for a highly predictable compounder, but Nike presently lacks that predictability. A 20%–30% discount to conservatively normalized value is more appropriate until revenue, margins, and cash conversion stabilize.

The low $30s could provide that discount if normalized value remains around $40–$45. It would not be attractive automatically if estimates and free cash flow continue falling.

4. Market weakness should influence entry timing, not define intrinsic value

The decline from approximately $67 to $35.99 confirms severe expectation resetting, but it does not prove either undervaluation or permanent impairment.

The downtrend matters because it may reflect:

  • continued earnings revisions;
  • institutional selling;
  • uncertainty about the recovery timetable; and
  • absent evidence of a durable operating inflection.

For a long-term investor, technical signals should not override intrinsic value. They can, however, prevent premature accumulation when fundamentals and expectations are both deteriorating. A sustained improvement in the medium-term trend would be supporting evidence, not a substitute for cash-flow recovery.

The options evidence should be disregarded. Zero reported open interest prevents reliable conclusions about positioning or liquidity, while unusually low reported implied volatility is not actionable without executable quotes and reasonable spreads.

Refined Investor Plan

Original plan

Keep Nike on a defensive watchlist rather than begin meaningful accumulation. Upgrade only after either a materially better valuation or credible operating stabilization.

That remains the correct base plan.

Positioning by risk tolerance

Conservative investor

  • Do not initiate a meaningful position at $35.99.
  • Avoid options and leverage.
  • Wait for operating evidence or a clear discount to updated normalized free cash flow.

Moderate-risk investor

  • An optional 0.5%–1% starter position is reasonable as a tracking investment.
  • Cap eventual exposure at approximately 2%–3%.
  • Fund it from the existing equity allocation rather than adding portfolio leverage.
  • Do not average down based solely on price weakness.

The starter position is participation in an uncertain recovery—not an endorsement that the shares have reached intrinsic-value support.

Requirements for additional purchases

A second tranche should require at least two of the following:

  1. Revenue stabilizes in North America or China.
  2. Inventory grows more slowly than sales.
  3. Promotional intensity declines and full-price sell-through improves.
  4. New products gain traction beyond legacy lifestyle franchises.
  5. Gross or operating margin improves sequentially.
  6. Free cash flow begins tracking adjusted net income.
  7. Forward earnings estimates stop declining.

A larger position should require evidence that revenue stabilization is producing sustainable margins and cash generation, rather than temporary benefits from inventory liquidation or cost cutting.

Conditions for ADVOCATE

Upgrade Nike to ADVOCATE if either:

  • updated normalized free cash flow supports intrinsic value materially above the market price, with roughly a 20%–30% discount while uncertainty remains; or
  • operational evidence shows improving full-price demand, disciplined inventory, margin recovery, and credible cash conversion.

A smaller valuation discount could be accepted after the business again becomes predictable.

Conditions for AVOID

Downgrade to AVOID if:

  • normalized earnings move materially toward $1.50 without a compensating price decline;
  • revenue continues contracting after inventory normalization;
  • promotions remain structurally elevated;
  • marketing and innovation spending rise without product traction;
  • free cash flow persistently trails earnings;
  • market-share losses spread across several core categories; or
  • deteriorating fundamentals are joined by genuine solvency stress.

Lessons Applied from Prior Assessments

Previous analyses made two opposite errors that should both be avoided:

  1. Do not let historical brand prestige dilute present deterioration. A great company can remain a poor stock while earnings expectations and cash flow are resetting.
  2. Do not convert a short-term price decline into automatic evidence of permanent impairment. Thirty-day outcomes are not the proper scorecard for a Buffett-style investment decision.

The improved approach separates:

  • Business quality: still above average;
  • Current predictability: weak;
  • Valuation: reasonable but not decisively cheap;
  • Entry timing: unconfirmed;
  • Portfolio exposure: small or zero until evidence improves.

Nike offers genuine turnaround optionality, but current profitability metrics do not yet establish sustainable owner earnings or a sufficient margin of safety.

Final Stance: WATCH

Scorecard

Overall 3.04 out of 5, weighted as shown.

DimensionWeightScoreWhat it measures
Business Quality30%3.25 / 5High returns, profitability, and Piotroski health support durability.
Valuation Support30%3.33 / 5Blends current price against available intrinsic value anchors and valuation ratios.
Financial Strength20%4.00 / 5Balance-sheet resilience reflects leverage and liquidity staying within safe ranges.
Growth Durability20%1.33 / 5Recent revenue, earnings, and free cash flow growth indicate how durable expansion looks.

The model

Every input behind the value range, so you can check the work or change an assumption and redo it yourself. Computed deterministically from SEC filings (fiscal 2026), updated Oct 4, 2026; the market price was $33.84. Values are estimates, not predictions.

Owner earnings (Buffett)

Discounts owner earnings: the cash the business generates for its owners after the spending needed to keep it running.

Value per share: $23.14 / $33.06 / $35.68 (conservative / base / optimistic)

Starting Owner Earnings$3.3B
Growth: conservative / base / optimistic (2016–2026)0.0% / 0.0% / 2.5%
Projection10 years
Discount rate8.6%
Terminal growth2.5%
Shares outstanding1484M
The history the growth rates come from (15 years)
2012$2.4B
2013$2.5B
2014$2.7B
2015$3.1B
2016$3.2B
2017$3.5B
2018$3.4B
2019$3.5B
2020$2.1B
2021$5.6B
2022$5.3B
2023$4.6B
2024$5.3B
2025$3.5B
2026$3.3B

Free cash flow

Discounts reported free cash flow: operating cash flow minus capital expenditure.

Value per share: $2.17 / $16.69 / $42.42 (conservative / base / optimistic)

Starting Free Cash Flow$1.4B
Growth: conservative / base / optimistic (2021–2026)-42.6% / 0.5% / 25.0%
Projection10 years
Discount rate9.4%
Terminal growth4.5%
Shares outstanding1484M
The history the growth rates come from (15 years)
2012$1.2B
2013$2.3B
2014$2.0B
2015$3.5B
2016$2.0B
2017$2.5B
2018$3.7B
2019$4.5B
2020$970M
2021$5.4B
2022$3.8B
2023$4.1B
2024$5.8B
2025$2.6B
2026$1.5B

Two-stage FCFF (Damodaran)

Projects revenue, operating margin and reinvestment, then discounts free cash flow to the firm at the weighted cost of capital.

Value per share: $40.27 / $51.30 / $69.47 (conservative / base / optimistic)

Starting Damodaran FCFF$3.2B
Growth: conservative / base / optimistic (2012–2026)1.4% / 5.0% / 9.4%
Projection10 years
Risk-free rate5.28%
Equity risk premium4.15%
Beta1.00
Cost of equity9.43%
After-tax cost of debt5.54%
Equity weight89%
WACC (discount rate)8.98%
Target operating margin (base)12.9%
High-growth stage5 years
Terminal growth2.5%
Shares outstanding1481M

This briefing is from Sep 25, 2026. A fresh one re-reads the latest filings and prices; running it takes a free account.

產生最新簡報 →Watch the video briefingGet the iPhone app

週一價值信

每週一封:傑出價值投資者買了什麼、賣了什麼,以及我們的看法。

請每週寄送一封 DeepValues 週一價值信給我。我可以隨時取消訂閱。僅供參考,不構成投資建議。 隱私政策